Viridian Therapeutics reported that its Phase 3 trial Reveal-2 met both primary endpoints for elegrobart in chronic thyroid eye disease (TED), lifting the stock as the company moves toward regulatory filings. In the study, the proptosis responder rate met the key measure needed for a U.S. FDA filing, while overall responder rate supported an EMA filing pathway. The drug is delivered subcutaneously via an at-home autoinjector and is a half-life-extended monoclonal antibody targeting the insulin-like growth factor-1 receptor. If approved, elegrobart would compete in TED against Amgen’s Tepezza (teprotumumab) and potentially within Viridian’s broader growth strategy as it also navigates a separate FDA review of veligrotug. Viridian positioned the Phase 3 results as clearing the way for a planned BLA filing in the first quarter of 2027.